AIDS and Hemophilia - Current Issues

• References

• 1 Chorba TL, Holman RC, Strine TW, Clarke MJ, Evatt BL. Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol 1994; 45: 112-21
• 2 Phillips AN, Sabin CA, Elford J. et al. Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. Br Med J 1994; 309: 309-313
• 3 Chiarotti F, Palombi M, Schinaia N, Ghirardini A, Bellocco R. Median time from seroconversion to AIDS in Italian HIV -positivehaemophiliacs: different parametric estimates. Stat Med 1994; 13: 163-175
• 4 Aronstam A, Congard B, Evans DI, Gazengel CF, Herberg U, Hill FG, Jones PM, Ljung R, Mauser-Bunschoten EP, Scheibel E. et al. HIV infection in haemophilia-a European cohort. Arch Dis Child 1993; 68: 521-524
• 5 Ehmann WC, Eyster ME, Wilson SE, Andes WA, Goedert JJ. Relationship of CD4 lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994; 7: 1095-1098
• 6 Eyster MW, Rabkin CS, Hilgartner MW, Aledort LM. et al. Human immunodeficiency virus-related conditions in children and adults with hemophilia: rates, relationshop to CD4 counts, and predictive value. Blood 1993; 81: 828-834
• 7 Telfer P, Sabin C, Devereux H. et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Brit J of Haematology 1994; 87: 555-561
• 8 Theorell T, Blomkvist V, Jonsson H. et al. Social support and the development of immune function in human immunodeficiency virus infection. Psychosomatic Med 1995; 57: 32-36
• 9 Gregg-Smith SJ, Pattison RM, Dodd CA, Giangrande PL. et al. Septic arthritis in haemophilia. J Bone& Joint Surg Br 1993; 75: 368-370
• 10 Merchan EC, Magallon M, Manso F, Martin-Villar J. Septic arthritis in HIV positive haemophiliacs. Four cases and a literature review. Int Orthop 1992; 16: 302-6
• 11 Brown SA, Majumdar G, Harrington C. et al. Effect of Splenectomy on HIV-related thrombocytopenia and progression of HIV infection in patients with severe haemophilia. Blood Coagul&Fibrinolysis 1994; 5: 393-397
• 12 Leissinger CA, Andes WA. Role of splenectomy in the management of hemophilic patients with human immunodeficiency virus-associated thrombocytopenic purpura. Am J Hematol 1992; 40: 207-209
• 13 Lane HC, Laughon BE, Falloon J. et al. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994; 120: 945-955
• 14 Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932-944
• 15 Womtergerst U, Niinivaara-Kreuzer K, Notheis G. et al. High-dose intravenous immunoglobulins in the treatment of adolescent adult HIV- infected hemophiliacs. Clin Investig 1994; 72: 122-126
• 16 Mannucci PM, Gringeri A, Savidge G. et al. Randomized double-blind, placebo-controlled trial of twice daily zidovine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. Brit J Haematol 1994; 86: 174-179
• 17 Jason J, Murphy L, Sleeper LA. et al. Immune and serologic profiles of HIV- infected and noninfected hemophilic children and adolescents. Hemophilia Growth and Development Study. Am J Hematol 1994; 46: 29-35
• 18 Bray GL, Kroner BL, Aikin S. et al. Loss of high-responder inhibitors in patients with severe hemophia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-379
• 19 Gjerset GF, Pike MC, Mosley JW. et al. Effect of low- and intermediate- purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group. Blood 1994; 84: 1666-1671
• 20 Mannucci PM, Brettler DB, Aledort LM. et al. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.. Blood 1994; 83: 1958-1962
• 21 Seremetis SV, Aledort LM, Bergman GE. et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects cm immune status. Lancet 1993; 342: 700-703
• 22 Smid WM, van derMeer J, Smit JW. et al. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated for two years with a monoclonal purified factor VIII concentrate. ThrombHaemost 1993; 69: 306-310
• 23 Hilgartner MW, Buckley JD, Operskalski EA. et al. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group. Lancet 1993; 341: 1373-1374
• 24 Prowse C. The effects of type of factor VIII concentrate used in haemophilia on T-helper cell number and inhibitor incidence. Blood Coagul Fibrinolysis 1992; 3: 597-604
• 25 de Biasi R, Rocino A, Miraglia E. et al. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-1922
• 26 Varon D, Schulman S, Dardik R. et al. High versus ultra-high purity factor VIII concentrate therapy -prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs. Thromb Haemost 1994; 72: 359-362
• 27 Mannucci PM, Gringeri A, de Biasi R. et al. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Thromb Haemost 1992; 67: 310-3
• 28 Hammer SM, Kessler HA, Saag MS. Issues in combination antiretroviral therapy — a review. J Acquir Immune Defic Syndr 1994; 7: S 24-S 37
• 29 Fischl MA, Stanley K, Collier AC. et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32
• 30 Zidovudine for the Prevention of HIV Transmission from Mother to Infant.. MMWR 1994; 43: 285-288
• 31 Ragni MV, Belle SH, Jaffe RA, Duerstein SL, Bass DC. et al. Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphomas and other malignancies in patients with hemophilia. Blood 1993; 81: 1889-1897
• 32 Anonymous. HIV transmission between two adolescent brothers with hemophilia. MMWR 1993; 42: 948-51
• 33 Brackmann SA, Gerritzen A, Oldenburg J. et al. Search for intrafamilial transmission of hepatitis C vims in hemophilia patients. Blood 1993; 81: 1077-1082
• 34 Ghirardini A, Chiarotti F, Schinaia N. Testing practices and spread of HIV among sexual partners of HIV-positive haemophiliacs in Italy. Gruppo Italiano Coagulopatie Congenite. AIDS 1993; 7: 573-577
• 35 Mayes SD, Elsesser V, Schaefer JH. et al. Sexual practices and AIDs knowledge among women partners of HIV-infected hemophiliacs. Public Health Rep 1992; 107: 504-514
• 36 Jacquez Jm, Koopman JS, Simon CP, Longini IM. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7: 1169-1184
• 37 Dublin S, Rosenberg PS, Goedert JJ. Patterns and predictors of high-risk sexual behavior in female partners of HIV-infected men with hemophilia. AIDS 1992; 6: 475-482
• 38 Klimes I, Catalan J, Garrod A. et al. Partners of men with HIV infection and haemophilia: controlled investigation of factors associated with psychological morbidity. AIDS Care 1992; 4: 149-156
• 39 Purcell RH, Mannucci PM, Gdovin S. et al. Virology of the Hepatitis A epidemic in Italy. Vox Sang 1994; 67: 2-7
• 40 Brackmann HH, Oldenburg J, Eishubinger AM. et al. Hepatitis A vims infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang 1994; 67: 3-8
• 41 Wagner N, Rotthauwe HW. Hepatitis C contributes to liver disease in children and adolescents with hemophilia. Klin Padiatr 1994; 206: 40-44
• 42 Kumar A, Kulkami R, Murray DL. etal. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41: 205-209
• 43 Ragni MV, Ndimibie OK, Rice EO. et al. The presence of hepatitis C vims (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV “seroconversion.”. Blood 1993; 82: 1010-1015
• 44 Troisi CL, Hollinger FB, Hoots WK. et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412-418
• 45 Mariani G, Baklaya R. et al. Prospective study of the evaluationof hepatitis C virus infectivity in a high-purity, solvent/detergent- treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione delTEmofilia. Transfusion 1993; 33: 814-818
• 46 Rollag H, Patou G, Pattison JR. et al. Prevalance of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 1991; 23: 675-9